Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy.
D000284:Administration, Oral; D001344:Autopsy; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004848:Epithelium / Q000473:pathology; D006417:Hematuria / Q000209:etiology; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D007680:Kidney Neoplasms / Q000188:drug therapy; D007938:Leukemia / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D009092:Mucous Membrane / Q000098:blood supply; D009447:Neuroblastoma / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D013684:Telangiectasis / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D001743:Urinary Bladder / Q000098:blood supply / Q000473:pathology; D001745:Urinary Bladder Diseases / Q000139:chemically induced* / Q000150:complications / Q000000981:diagnostic imaging / Q000473:pathology; D014567:Urography; D009396:Wilms Tumor / Q000188:drug therapy
D003520:Cyclophosphamide